Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin‐Converting Enzyme Inhibitor or Angiotensin‐Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure
Journal of the American Heart Association- United Kingdom
doi 10.1161/jaha.118.011089
Full Text
Abstract
Available in
Date
May 7, 2019
Authors
Publisher
Ovid Technologies (Wolters Kluwer Health)